Integra LifeSciences Holdings (IART)
Quick ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 276,402 | 273,732 | 309,192 | 307,367 | 456,661 | 511,937 | 447,152 | 407,092 | 513,448 | 470,231 | 397,414 | 408,976 | 470,166 | 396,279 | 360,981 | 357,712 | 198,911 | 207,981 | 176,084 | 157,025 |
| Short-term investments | US$ in thousands | 32,694 | 19,938 | 20,200 | 15,659 | 0 | 13,111 | 4,369 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Receivables | US$ in thousands | 259,327 | 256,270 | 258,663 | 253,995 | 263,465 | 248,268 | 237,361 | 234,010 | 231,831 | 222,232 | 229,823 | 223,542 | 225,532 | 218,184 | 179,143 | 245,546 | 275,296 | 281,119 | 296,507 | 279,072 |
| Total current liabilities | US$ in thousands | 306,980 | 355,712 | 377,496 | 282,293 | 320,906 | 304,452 | 295,596 | 315,833 | 340,021 | 332,858 | 318,756 | 412,301 | 401,013 | 255,146 | 212,415 | 246,485 | 331,309 | 302,641 | 315,111 | 288,106 |
| Quick ratio | 1.85 | 1.55 | 1.56 | 2.04 | 2.24 | 2.54 | 2.33 | 2.03 | 2.19 | 2.08 | 1.97 | 1.53 | 1.73 | 2.41 | 2.54 | 2.45 | 1.43 | 1.62 | 1.50 | 1.51 |
December 31, 2023 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($276,402K
+ $32,694K
+ $259,327K)
÷ $306,980K
= 1.85
The quick ratio of Integra Lifesciences Holdings Corp has shown some fluctuations over the past eight quarters. The company's quick ratio ranged from a low of 1.85 in Q2 2023 to a high of 2.90 in Q3 2022. The quick ratio measures the company's ability to meet its short-term obligations with its most liquid assets, excluding inventory.
A quick ratio above 1 indicates that the company has sufficient liquid assets to cover its short-term liabilities. Integra Lifesciences Holdings Corp consistently maintained a quick ratio above 2, with the highest value in Q3 2022. This indicates a strong liquidity position and suggests that the company is well-equipped to meet its short-term obligations without relying heavily on inventory.
The decreasing trend in the quick ratio from Q3 2022 to Q2 2023 may indicate a potential reduction in the company's ability to cover short-term liabilities with liquid assets. However, the quick ratio recovered slightly in Q4 2023 to 2.18, although it remains below the previous highs seen in earlier quarters.
Overall, while there has been some variability in the quick ratio of Integra Lifesciences Holdings Corp over the analyzed period, the company generally maintains a strong liquidity position, which is a positive indicator for its financial health and ability to meet short-term obligations.
Peer comparison
Dec 31, 2023